BlackRock’s Inhibrx, Inc. Common Stock INBX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,751,705
| Closed | -$96.2M | – | 5453 |
|
|
2024
Q1 | $96.2M | Buy |
2,751,705
+36,033
| +1% | +$1.31M | ﹤0.01% | 2068 |
|
|
2023
Q4 | $103M | Buy |
2,715,672
+175,899
| +7% | +$3.77M | ﹤0.01% | 2056 |
|
|
2023
Q3 | $46.6M | Sell |
2,539,773
-6,830
| -0.3% | -$143K | ﹤0.01% | 2434 |
|
|
2023
Q2 | $66.1M | Buy |
2,546,603
+213,678
| +9% | +$4.99M | ﹤0.01% | 2314 |
|
|
2023
Q1 | $44M | Sell |
2,332,925
-83,263
| -3% | -$1.94M | ﹤0.01% | 2532 |
|
|
2022
Q4 | $59.5M | Buy |
2,416,188
+225,670
| +10% | +$6.63M | ﹤0.01% | 2345 |
|
|
2022
Q3 | $39.3M | Buy |
2,190,518
+213,407
| +11% | +$3.85M | ﹤0.01% | 2630 |
|
|
2022
Q2 | $22.4M | Buy |
1,977,111
+74,964
| +4% | +$1.1M | ﹤0.01% | 3025 |
|
|
2022
Q1 | $42.4M | Buy |
1,902,147
+7,680
| +0.4% | +$196K | ﹤0.01% | 2681 |
|
|
2021
Q4 | $82.7M | Buy |
1,894,467
+231,936
| +14% | +$9.28M | ﹤0.01% | 2336 |
|
|
2021
Q3 | $55.4M | Buy |
1,662,531
+165,358
| +11% | +$5.03M | ﹤0.01% | 2596 |
|
|
2021
Q2 | $41.2M | Buy |
1,497,173
+897,465
| +150% | +$18.7M | ﹤0.01% | 2829 |
|
|
2021
Q1 | $12M | Buy |
599,708
+104,676
| +21% | +$3.06M | ﹤0.01% | 3465 |
|
|
2020
Q4 | $16.3M | Buy |
495,032
+397,934
| +410% | +$10.6M | ﹤0.01% | 3114 |
|
|
2020
Q3 | $1.75M | Buy |
+97,098
| New | +$1.76M | ﹤0.01% | 3942 |
|
Other funds holding INBX
BlackRock's INBX Position: Q2 2024 in Review
BlackRock sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 2,751,705 shares — an estimated $96.2M sold.
BlackRock first reported a position in INBX in Q3 2020 and held it in 15 quarters. The position peaked at $103M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.
- BlackRock reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 2,751,705 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $96.2M.
- BlackRock first reported a position in Inhibrx, Inc. Common Stock in Q3 2020 and held it in 15 quarters.
- BlackRock's Inhibrx, Inc. Common Stock position peaked at $103M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.